Innovate Clinical Research

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)3 trials
• Obesity2 trials
• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• Stroke1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 11 trial

Status

• Recruiting3 trials
• Not yet recruiting2 trials
• Completed1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Alphyn Biologics1 trial
• BeiGene1 trial
• Hemay Pharmaceutical PTY. LTD.1 trial

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: Rachel Graham (principal investigator)

• Not yet recruiting

  To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis

  NCT07877155· Phase 2· Hemay Pharmaceutical PTY. LTD.· Source

  Contact: McGirr, Dr

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

  Contact: Rachel Graham (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Anthony McGirr (principal investigator)

• Recruiting

  Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

  NCT06855745· Phase 2· Alphyn Biologics· Source

  Contact: Dr Linda Chan

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• Chronic kidney disease1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

  NCT06342713· Phase 1· BeiGene· Source